Ligand Pharmaceuticals Inc Liquidation Value

Ligand Pharmaceuticals (LGND) is a royalty aggregator with a balance sheet dominated by financial assets rather than tangible property. As of March 31, 2026, total assets were $1.53B against total liabilities of $534.8M, producing GAAP book equity of $997.3M. Under a liquidation lens, the recovery picture is structurally negative relative to book equity because the bulk of the asset base carries near-zero liquidation value.

The largest asset blocks are: (1) short-term investments of $664.3M in marketable debt and equity securities, recoverable at close to face in an orderly wind-down given Level 1/2 classification; (2) financial royalty assets (net carrying value $205.7M, estimated fair value $303.9M per management's DCF at 13-35% discount rates), which under the liquidation lens receive a 0% haircut in the XBRL schema since they are classified as intangibles/financial assets without a standard haircut category—but a practitioner would apply a distressed-sale discount, likely 40-60% off fair value, producing $120-180M of recoverable value; (3) intangible assets net of $217.3M and goodwill of $101.5M, both assigned 0% recovery under the liquidation lens; (4) inventory of $13.3M (Captisol), recoverable at roughly 60%, or ~$8M; (5) accounts receivable of $53.4M at 90-95% recovery, or ~$49-51M.

On the liability side, the dominant obligation is the 0.75% Convertible Senior Notes due 2030 with $460M face amount ($446.9M carrying value net of issuance costs), held at face in liquidation. The revolving credit facility is undrawn ($124.4M available). Operating lease liabilities total $5.1M ($1.1M current, $4.0M noncurrent). Contingent liabilities (CyDex, Metabasis CVRs) total $3.9M fair value. Deferred tax liabilities net approximately $14.1M ($22.6M DTL less $8.5M DTA).

Applying standard liquidation haircuts: liquid assets (cash $115M, short-term investments $664M at ~98%) plus AR recovery (~$50M) plus inventory (~$8M) plus financial royalty assets (distressed at ~50% of fair value, ~$150M) against $460M notes + $37M other liabilities produces a rough equity recovery in the range of $490-560M, well below the $997M GAAP book value. The MFFAIS CLV of $70M and OLV of $137M reflect more severe haircut assumptions on financial royalty assets and intangibles.

Key changes QoQ: financial royalty assets declined from $219.7M to $205.7M (gross $222.4M to $208.4M) primarily due to Qarziba principal paydowns ($118.1M to $103.2M net). Pelthos equity investments (common + preferred) fell $49.2M in fair value during Q1 2026, recorded as an unrealized loss. The 2030 Notes were issued in August 2025 and represent the dominant new liability vs. the prior 10-K filing. A subsequent-event acquisition of XOMA for approximately $739M in cash (expected Q3 2026 close) would substantially reduce liquid asset balances and increase royalty intangible assets—not reflected on this balance sheet. The filing does not separately XBRL-tag the XOMA purchase price or the pending liability, consistent with its post-period status.